Drug Trial Radar · NCT06075953
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Feb 17, 2024
Primary completion
Nov 2028
Study completion Nov 2033
Sponsor
- Lead sponsor
- QuantumLeap Healthcare CollaborativeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Participants will be asked to receive control hormonal therapy or an investigational hormonal therapy treatment. Participants will be asked to return for evaluation with MRI at three months and six months. Depending on the evaluation participants will have the option to continue on the treatment. If the evaluation suggests surgery is recommended, the participant will discontinue the study treatment and will undergo surgery. In addition to the treatment and MRI evaluation, participants will be asked to provide blood sample to understand their immune status, provide saliva sample for genetic testing, provide the study with a portion of the tissue or slides generated from tissue removed during surgery performed as part of their standard of care.
Conditions
- Ductal Carcinoma in Situ
Interventions
TamoxifenDrug
For premenopausal women: 20 mg tamoxifen orally daily (standard dose) or 10 mg every other day (low dose). For postmenopausal women who are not tolerating an AI, investigators can change them to the low dose (10 mg every other day) or standard dose (20 mg) of tamoxifen.
ExemestaneDrug
For postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, or reduced exemestane dosing: 25 mg 3 times per week orally
LetrozoleDrug
For postmenopausal women: standard oral doses of AI of choice: letrozole 2.5 mg daily.
AnastrazoleDrug
For postmenopausal women: standard oral doses of AI of choice: anastrozole 1 mg daily.
Testosterone + AnastrazoleDrug
Investigational drug. Both pre- and post- menopausal subjects. 100mg testosterone in combination with 4mg anastrazole administered subcutaneously every 3 months for up to 3 years.
ElacestrantDrug
Investigational drug. Both pre- and post- menopausal subjects. Elacestrant 400mg PO with food once daily up to 36 months.
Z-endoxifenDrug
Investigational drug. Both pre- and post- menopausal subjects. (z)-endoxifen 10mg delayed release capsule 1 hour before a meal or 2 hours after a meal once daily for up to 36 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patients remaining on active surveillance at 7 monthsTime frame: 7 months
Locations
31 sites in 1 country. Site status is shown where the registry gives one.
Berkeley Outpatient Center
Berkeley, California · Recruiting
City of Hope -Duarte Cancer Center
Duarte, California · Recruiting
City of Hope - Lennar Foundation Cancer Center
Irvine, California · Recruiting
UCLA
Los Angeles, California · Recruiting
UCSF
San Francisco, California · Recruiting
City of Hope
South Pasadena, California · Recruiting
John Muir Health
Walnut Creek, California · Recruiting
MedStar Washington Hospital Center
Washington D.C., District of Columbia · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Winship Cancer Institute, Emory University
Atlanta, Georgia · Recruiting
University of Chicago Medical Center
Chicago, Illinois · Recruiting
Maple Grove Cancer Center
Maple Grove, Minnesota · Recruiting
Hennepin Healthcare -Minneapolis
Minneapolis, Minnesota · Recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
Health Partners - Frauenshuh Cancer Center
Saint Louis Park, Minnesota · Recruiting
Health Partners - Regions Hospital
Saint Paul, Minnesota · Recruiting
Englewood Hospital and Medical Center
Englewood, New Jersey · Recruiting
Mount Sinai Union Square
New York, New York · Recruiting
Mount Sinai Chelsea
New York, New York · Recruiting
Mount Sinai West
New York, New York · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
Montefiore Medical Center (Hutchinson Campus Tower 1)
The Bronx, New York · Recruiting
Duke Cancer Institute
Durham, North Carolina · Recruiting
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina · Recruiting
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania · Active not recruiting
Paoli Hospital
Paoli, Pennsylvania · Active not recruiting
Lankenau Medical Center
Wynnewood, Pennsylvania · Active not recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Huntsman Cancer Institute
Salt Lake City, Utah · Recruiting
Virginia Commonwealth University
Richmond, Virginia · Recruiting
Univesity of Washington (UW) / Fred Hutchinson Cancer Center (FHCC)
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.